AJTMH HINARI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 63(3), 2000, pp. 111-118
Copyright © 2000 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lauria-Pires, L
Right arrow Articles by Teixeira, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lauria-Pires, L
Right arrow Articles by Teixeira, A.
Related Collections
Right arrow Trypanosomiasis
Right arrow Chagas Disease
American Journal of Tropical Medicine and Hygiene, Vol 63, Issue 3, 111-118
Copyright © 2000 by American Society of Tropical Medicine and Hygiene

Research Articles


Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives

L Lauria-Pires, MS Braga, AC Vexenat, N Nitz, A Simoes-Barbosa, DL Tinoco, and AR Teixeira

A randomized ten-year follow-up study involving 91 Chagas patients and 41 uninfected controls was undertaken to determine the effectiveness of nitroderivative therapy. Anti-Trypanosoma cruzi antibodies were consistently lower one year after treatment than 10 years thereafter (P < 0.001). The blood of all treated and 93.7% of untreated Chagas patients yielded polymerase chain reaction (PCR) product from probes annealing to T. cruzi nuclear DNA, indicating active infection. Competitive PCR showed means +/- standard deviations of 20.1+/-22.6 T. cruzi/ml of blood from untreated and 13.8+/-14.9 from treated Chagas patients, but the differences between means were not statistically significant (P > 0.05). Electrocardiograms recorded a gamut of alterations several-fold more frequent in Chagas patients, regardless of treatment, than in uninfected controls (P < 0.001). These results show that nitroderivative therapy for T. cruzi infections is unsatisfactory and cannot be recommended since it fails to eradicate the parasite or change the progression of heart disease in chronic Chagas patients.


This article has been cited by other articles:


Home page
 Postgrad. Med. J.Home page
A R L Teixeira, N Nitz, M C Guimaro, C Gomes, and C A Santos-Buch
Chagas disease
Postgrad. Med. J., December 1, 2006; 82(974): 788 - 798.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
X. Coronado, I. Zulantay, M. Rozas, W. Apt, G. Sanchez, J. Rodriguez, S. Ortiz, and A. Solari
Dissimilar distribution of Trypanosoma cruzi clones in humans after chemotherapy with allopurinol and itraconazole
J. Antimicrob. Chemother., July 1, 2006; 58(1): 216 - 219.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
R. Viotti, C. Vigliano, B. Lococo, G. Bertocchi, M. Petti, M. G. Alvarez, M. Postan, and A. Armenti
Long-Term Cardiac Outcomes of Treating Chronic Chagas Disease with Benznidazole versus No Treatment: A Nonrandomized Trial
Ann Intern Med, May 16, 2006; 144(10): 724 - 734.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Society of Tropical Medicine and Hygiene.